Design, development and evaluation of Nano Based Novel Ophthalmic Drug Delivery System for Glaucoma
Main Article Content
Abstract
In order to treat glaucoma, the in-situ gel of the chitosan nanoparticles loaded with Carteolol was developed for this investigation. By using the ionotropic gelation approach, Carteolol-loaded chitosan nanoparticles (Carteolol-CHNPs) were created. They were then further improved using the 3-factor and 3-level Box–Behnken design. Three factors were chosen as independent variables: chitosan (A), sodium tripolyphosphate (B), and stirring speed (C). They were shown to have an impact on loading capacity (LC as Y3), entrapment efficiency (EE as Y2), and particle size (PS as Y1). Gel containing nanoparticles was assessed for rheological, gelation time, gelling temperature, and transcorneal permeability. Furthermore, transcorneal permeation drug release investigations and intraocular pressure (IOP) for improved gel were carried out in vitro. Using a rabbit model, the biocompatibility of formulations was examined. Optimized Carteolol-chitosan nanoparticles are incorporated into a thermosensitive in-situ gel matrix to enhance precorneal residence time without irritating the eyes and to facilitate the sustained release of Carteolol through the cornea for efficient glaucoma treatment.
Article Details
References
V. Mishra. Acetazolamide encapsulated dendritic nano-architectures for effective glaucoma management in rabbits. Int. J. Pharm. 2014. 34:786-98.
L. Lalu. Novel nanosystems for the treatment of ocular inflammation: current paradigms and future research directions J. Contr. Release. 2017; 3(2):678-84.
N. Thomas. In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS). J. Contr. Release. 2012; 65:876.
Barse R., Kokare C., Tagalpallewar A. Influence of hydroxyl propyl methylcellulose and poloxamer composite on developed ophthalmic in situ gel: ex vivo and in vivo characterization. J Drug Deliv Sci Technol. 2016; 33:66–74.
Addepalli UK., Jonnadula GB., Garudadri CS., Khanna RC., Papas EB. Prevalence of primary glaucoma as diagnosed by study optometrists of L. V. Prasad eye institute–glaucoma epidemiology and molecular genetics study. Ophthalmic Epidemiol. 2019; 26 (3):150–54.
Barse RK., Tagalpallewar AA., Kokare CR., Sharma JP., Sharma PK. Formulation and ex vivo–in vivo evaluation of PH-triggered brimonidine tartrate in situ gel for the glaucoma treatment using application of 32 factorial design. Drug Dev Ind Pharm. 2018; 44 (5):800–07.
Morsi N., Ghorab D., Refat H., Teba H. Ketoroloac tromethamine loaded nanodispersion incorporated into thermosensitive in situ gel for prolonged ocular delivery. Int J Pharm. 2016; 506(1–2):57– 67.
Silva AC., Amaral MH., González-Mira E., Santos D., Ferreira D. Solid Lipid Nanoparticles (SLN) - Based hydrogels as potential carriers for oral transmucosal delivery of risperidone: preparation and characterization studies. Colloids Surfaces B Biointerfaces. 2012; 93:241–48.
Bateman DN, Clark R, Azuara-Blanco A, Bain M, Forrest J. The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophtalmological health care. Br J Ophtalmol. 2002;86(5):551–4.
Kastrup EK. Drug facts and comparisons. USA: Wolters Kluwer Health; 2012. p. 3193–4.
Kaur IP, Aggarwal D, Singh H, Kakkar S. Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system. Graefes Arch Clin Exp Ophthalmol. 2010;248(10):1467–72.
Kouchak M. In situ gelling systems for drug delivery. Jundishapur J Nat Pharm Prod. 2014;9(3):e20126.
Lin H, Sung KC. Carbopol®/pluronic phase change solutions for ophthalmic drug delivery. J Control Release. 2000;69:379–88.
Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release. 2001;73(2–3):205–11.
Gupta S, Vyas SP. Carbopol/chitosan based pH triggered in situ gelling system for ocular delivery of timolol maleate. Sci Pharm. 2010;78(4):959–76.
Moiseev RV, Steele F, Khutoryanskiy VV. Polyaphron formulations stabilised with different water-soluble polymers for ocular drug delivery. Pharmaceutics. 2022;14(5):926. doi: 10.3390/pharmaceutics14050926.
Radomska-Soukharev A, Wojciechowska J. Microemulsions as potential ocular drug delivery systems: phase diagrams and physical properties depending on ingredients. Acta Pol Pharm. 2005;62(6):465–471.
. Doshi U, Xu J. Effect of viscosity, surface tension and mucoadhesion on ocular residence time of lubricant eye drops. Invest Ophthalmol Vis Sci. 2009;50(13):4641–4641.
Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm. 2011;403(1–2):185–191. doi: 10.1016/j.ijpharm.2010.10.013.
Stahl U, Willcox M, Stapleton F. Osmolality and tear film dynamics. Clin Exp Optom. 2012;95(1):3–11. doi: 10.1111/j.1444-0938.2011.00634.x.
Murube J. Tear osmolarity. Ocul Surf. 2006;4(2):62–73. doi: 10.1016/S1542-0124(12)70028-9.
Varela-Fernández R, Díaz-Tomé V, Luaces-Rodríguez A, et al. Drug delivery to the posterior segment of the eye: biopharmaceutic and pharmacokinetic considerations. Pharmaceutics. 2020;12(3):269. doi: 10.3390/pharmaceutics12030269.
Shetty R, Naidu JR, Nair AP, et al. Distinct ocular surface soluble factor profile in human corneal dystrophies. Ocul Surf. 2020;18(2):237–248. doi: 10.1016/j.jtos.2019.11.007.
Romeo A, Musumeci T, Carbone C, et al. Ferulic acid-loaded polymeric nanoparticles for potential ocular delivery. Pharmaceutics. 2021;13(5):687. doi: 10.3390/pharmaceutics13050687.
Carnevale C, Riva I, Roberti G, et al. Confocal microscopy and anterior segment optical coherence tomography imaging of the ocular surface and bleb morphology in medically and surgically treated glaucoma patients: a review. Pharmaceuticals (Basel) 2021;14(6):581. doi: 10.3390/ph14060581.
Khalil IA, Ali IH, El-Sherbiny IM. Noninvasive biodegradable nanoparticles-in-nanofibers single-dose ocular insert: in vitro, ex vivo and in vivo evaluation. Nanomedicine (Lond) 2019;14(1):33–55. doi: 10.2217/nnm-2018-0297.